A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: Comparison of ranibizumab and bevacizumab

Current Medical Research and Opinion

Volumn 27, Issue 7, 2011, Pages 1465-1475

  Mitchell, Paul ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

Author keywords

Age related macular degeneration; AMD; Avastin; Bevacizumab; Lucentis; Ranibizumab; VEGF

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN ANTIBODY;

DRUG EFFICACY; DRUG SAFETY; ENDOPHTHALMITIS; EVIDENCE BASED MEDICINE; EYE INFLAMMATION; HUMAN; OUTCOME ASSESSMENT; PHOTODYNAMIC THERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA MACULA AGE RELATED DEGENERATION; RETINA TEAR; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UVEITIS; VISUAL ACUITY; VITREOUS HEMORRHAGE;

ALGORITHMS; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; HUMANS; MACULAR DEGENERATION; NEOVASCULARIZATION, PATHOLOGIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79958786721     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.585394     Document Type: Review

References (66)

1. Jager RD, Mieler WF, Miller JW. Age-related macular degeneration. N Engl J Med 2008;358:2606-17.
2. Resnikoff S, Pascolini D, Etya'ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ 2004;82:844-51. (Pubitemid 39573742)
3. Gehrs KM, Anderson DH, Johnson LV, et al. Age-related macular degeneration - emerging pathogenetic and therapeutic concepts. Ann Med 2006; 38:450-71. (Pubitemid 44767496)
4. Emerson MV, Lauer AK. Current and emerging therapies for the treatment of age-related macular degeneration. Clin Ophthalmol 2008;2:377-88.
5. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-7. (Pubitemid 24356306)
6. Kliffen M, Sharma HS, Mooy CM, et al. Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol 1997;81:154-62. (Pubitemid 27092496)
7. Boyd SR, Zachary I, Chakravarthy U, et al. Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion. Arch Ophthalmol 2002;120:1644-50. (Pubitemid 36401798)
8. Kvanta A, Algvere PV, Berglin L, et al. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 1996;37:1929-34. (Pubitemid 26324159)
9. Gragoudas ES, Adamis AP, Cunningham Jr. ET, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351:2805-16. (Pubitemid 40051904)
10. Chakravarthy U, Adamis AP, Cunningham Jr. ET, et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular agerelated macular degeneration. Ophthalmology 2006;113:1508 e1-25.
11. D'Amico DJ, Masonson HN, Patel M, et al. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology 2006;113: 992-1001 e6.
12. Chen Y, Wiesmann C, Fuh G, et al. Selection and analysis of an optimized anti- VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol 1999;293:865-81. (Pubitemid 29527672)
13. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular agerelated macular degeneration. N Engl J Med 2006;355:1419-31. (Pubitemid 44511557)
14. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355:1432-44. (Pubitemid 44511558)
15. Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 2009;116:57-65 e5.
16. Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: Phase III clinical trial results. Ophthalmol Clin North Am 2006;19:361-72. (Pubitemid 44279358)
17. Bashshur ZF, Schakal A, Hamam RN, et al. Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration. Arch Ophthalmol 2007;125:1357-61. (Pubitemid 47606600)
18. Hahn R, Sacu S, Michels S, et al. [Intravitreal bevacizumab versus verteporfin and intravitreal triamcinolone acetonide in patients with neovascular agerelated macula degeneration]. Ophthalmologe 2007;104:588-93.
19. Lazic R, Gabric N. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2007;114:1179-85. (Pubitemid 46829388)
20. Potter MJ, Claudio CC, Szabo SM. A randomised trial of bevacizumab and reduced light dose photodynamic therapy in age-related macular degeneration: the VIA study. Br J Ophthalmol 2010;94:174-9.
21. Sacu S, Michels S, Prager F, et al. Randomised clinical trial of intravitreal Avastin vs photodynamic therapy and intravitreal triamcinolone: long-term results. Eye (Lond) 2009;23:2223-7.
22. Subramanian ML, Ness S, Abedi G, et al. Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial. Am J Ophthalmol 2009;148:875-82 e1.
23. Tufail A, Patel PJ, Egan C, et al. Avastin (Bevacizumab) for choroidal neovascularisation in age-related macular degeneration (ABC) trial. BMJ 2010; 340:c2459.
24. Weigert G, Michels S, Sacu S, et al. Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study. Br J Ophthalmol 2008;92:356-60. (Pubitemid 351363530)
25. Genentech. Avastin prescribing information. 2010.
26. Kahook MY, Liu L, Ruzycki P, et al. High-molecular-weight aggregates in repackaged bevacizumab. Retina 2010;30:887-92.
27. Novartis. Lucentis prescribing information. 2006.
28. USP 28/NF 23, Chapter57884"Particulate Matter in Injections" United States Pharmacopeial Convention, Inc Rockville, MD, 2005.
29. USP 28/NF 23 Chapter57894"Particulate Matter in Ophthalmic Solutions". United States Pharmacopeial Convention, Inc Rockville, MD, 2005.
30. Sharma S. The comparative safety of intravitreal bevacizumab versus ranibizumab for retinal disease. 28th Annual Meeting of the American Society of Retina Specialists; 2010 August 28-September 1, 2010; Vancouver, BC, Canada, 2010.
31. Wong TY, Liew G, Mitchell P. Clinical update: new treatments for age-related macular degeneration. Lancet 2007;370:204-6. (Pubitemid 47069522)
32. Liew G, Mitchell P. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2007;356:747-8; author reply 9-50.
33. Oxford Centre for Evidence-based Medicine - Levels of Evidence (March 2009). Available at http://www.cebm.net/index.aspx?o¼1025. Accessed October 2010.
34. Mitchell P, Korobelnik JF, Lanzetta P, et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol 2010;94:2-13.
35. Heier JS, Boyer DS, Ciulla TA, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. Arch Ophthalmol 2006;124:1532-42. (Pubitemid 44748725)
36. Bressler NM, Chang TS, Fine JT, et al. Improved vision-related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Arch Ophthalmol 2009;127:13-21.
37. Chang TS, Bressler NM, Fine JT, et al. Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol 2007; 125:1460-9. (Pubitemid 350106676)
38. Regillo CD, Brown DM, Abraham P, et al. Randomized, doublemasked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008; 145:239-48.
39. Antoszyk AN, Tuomi L, Chung CY, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthalmol 2008;145:862-74.
40. Rosenfeld PJ, Heier JS, Hantsbarger G, et al. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular agerelated macular degeneration. Ophthalmology 2006;113:623-32e1.
41. Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology 2006;113:633-42e4.
42. Boyer DS, Heier JS, Brown DM, et al. A phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology 2009;116:1731-9.
43. Tano Y, Ohji M. EXTEND-I: safety and efficacy of ranibizumab in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Acta Ophthalmol 2010;88:309-16.
44. Subramanian ML, Abedi G, Ness S, et al. Bevacizumab vs ranibizumab: one year outcomes of a head-to-head, prospective, double-masked, randomized clinical trial. Presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), May 2, 2010.
45. Schmucker C, Antes G, Lelgemann M, et al. Treatment of age-related macular degeneration: evidence report. German Cochrane Center, 25 September, 2009.
46. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006;90:1344-9. (Pubitemid 44702055)
47. Lynch SS, Cheng CM. Bevacizumab for neovascular ocular diseases. Ann Pharmacother 2007;41:614-25. (Pubitemid 46625484)
48. Schmucker C, Antes G, Lelgemann M. A systematic review on the effect of bevacizumab in exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2010;248:451-2.
49. McGimpsey SJ, Gillies MC. Treatment of macular degeneration - controversy and hope. Br J Ophthalmol 2008;92:436-7. (Pubitemid 351363557)
50. Roth DB, King A, Weiss M, et al. Systemic adverse events after bevacizumab. Ophthalmology 2009;116:1226 e1.
51. Dafer RM, Schneck M, Friberg TR, et al. Intravitreal ranibizumab and bevacizumab: a review of risk. Semin Ophthalmol 2007;22:201-4. (Pubitemid 47346972)
52. Schmidt-Erfurth U. Clinical safety of ranibizumab in age-related macular degeneration. Expert Opin Drug Saf 2010;9:149-65.
53. Genentech. Genentech: Reports of intraocular inflammatory reactions after intravitreal injection with AVASTIN. Available at http://www.fiercebiotech. com/press-releases/genentech-reports-intraocular-inflammatory-reactionsafter- intravitreal-injection-ava. Accessed July 2010.
54. HealthCanada. Reports of eye inflammation, endophthalmitis, and toxic anterior segment syndrome (TASS) following off-label intravitreal use of AVASTIN® (bevacizumab). Available at http://www.hc-sc.gc.ca/dhp-mps/medeff/ advisories-avis/prof/-2008/AVASTIN®4-hpc-cps-eng.php. Accessed July 2010.
55. Holland S. Update on bevacizumab (Avastin)-associated post-operative inflammation (TASS, Sterile Endophthalmitis). Canadian Ophthalmological Society newsletter (http://wwweyesiteca/Perspectives/September2009/September-ephp) 2009.
56. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13. (Pubitemid 35472129)
57. Tan JS, Wang JJ, Liew G, et al. Age-related macular degeneration and mortality from cardiovascular disease or stroke. Br J Ophthalmol 2008;92:509-12. (Pubitemid 351497979)
58. Alexander SL, Linde-Zwirble WT, Werther W, et al. Annual rates of arterial thromboembolic events in Medicare neovascular age-related macular degeneration patients. Ophthalmology 2007;114:2174-8. (Pubitemid 350181138)
59. Tan JS, Mitchell P, Smith W, et al. Cardiovascular risk factors and the longterm incidence of age-related macular degeneration: the Blue Mountains Eye Study. Ophthalmology 2007;114:1143-50. (Pubitemid 46829381)
60. Ferrara N, Damico L, Shams N, et al. Development of ranibizumab, an antivascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006;26:859-70. (Pubitemid 44547437)
61. Curtis LH, Hammill BG, Schulman KA, et al. Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 2010;128:1273-9.
62. Ross JS, Madigan D, Hill KP, et al. Pooled analysis of rofecoxib placebocontrolled clinical trial data: lessons for postmarket pharmaceutical safety surveillance. Arch Intern Med 2009;169:1976-85.
63. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006;113:1695 e1-15.
64. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007;114:855-9. (Pubitemid 46635858)
65. Dib E, Maia M, Longo-Maugeri IM, et al. Subretinal bevacizumab detection after intravitreous injection in rabbits. Invest Ophthalmol Vis Sci 2008; 49:1097-100.
66. Nomoto H, Shiraga F, Kuno N, et al. Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits. Invest Ophthalmol Vis Sci 2009;50:4807-13